<DOC>
	<DOC>NCT00581308</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety and efficacy of the GORE® HELEX® Septal Occluder in the treatment of ostium secundum atrial septal defects (ASDs).</brief_summary>
	<brief_title>Long-term Safety Study of the GORE® HELEX® Septal Occluder</brief_title>
	<detailed_description>The GORE® HELEX® Septal Occluder is an approved medical device indicated for the transcatheter closure of atrial septal defects (ASDs). The purpose of this study is to evaluate the long-term safety and efficacy of the GORE® HELEX® Septal Occluder in the treatment of ostium secundum atrial septal defects (ASDs). This is an FDA Condition of Approval Study. All subjects enrolled in this study will be followed for long-term safety and efficacy of the occluder device through 5 years.</detailed_description>
	<mesh_term>Heart Septal Defects</mesh_term>
	<mesh_term>Heart Septal Defects, Atrial</mesh_term>
	<criteria>ASD less than or equal to 18 mm. Conditions that would confound treatment of ASD or complicate distinguishing onset of adverse events. Unable to accommodate device delivery catheter.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>atrial septal defect, septal occluder, HELEX</keyword>
</DOC>